Construction of Plasmids and Recombinant Virus. Standard cloning techniques were used to construct the plasmids. The plasmid pIFNSS contains a 0.6-kb EcoRI/BamHI fragment coding for the signal peptide and coding sequence of IFN-conl (11). The plasmid pAd5/IFN was generated by inserting the 0.6-kb fragment from pIFNSS into the Xba I site of the pFG-dxl by blunt end ligation. Restriction fragments used for ligation were purified from agarose gels using Geneclean (Bio 101). PFG-dxl contains 40% of the right end of the adenovirus genome with a deletion from 78.5 to 84.7 map units. This 1.9-kb deletion removes most of the E3 region but leaves the E3 promoter and termination site. 293 cells were cotransfected with the plasmid pAd5/IFN and EcoRI digested adenovirus-5 DNA to rescue the recombinant virus (12), which was plaque purified twice and analyzed by restriction enzyme digestion.
ad5/wt, ad5/lfu, and ad5/IFN were added to monolayers of 293 cells at a multiplicity of infection (moi) of 50. Fig. 1C) . This was significantly less effective than using ad5/IFN. Treatment with IFN-conl itself at clinically relevant doses at 3-day intervals (100,000 units/ml) resulted in a significant decrease in growth, although less than with any of the other treatments. Fig. 3A) . There was no significant difference between controls and ad5/wt or ad5/lfu. Similar experiments to those described above were done with established tumors. ad5/IFN did inhibit the development of the established tumor and temporarily inhibited growth, whereas both wild-type virus and ad5/lfu had no effect on tumor growth. IFN-conl at 100,000 units every 2 or 3 days had a slight effect on tumor development (data not shown).
In Vitro Effects of Recombinant Virus. To examine whether the differences seen in the response to wild-type and recombinant virus could be seen in culture, MDA-MB-435 cells were infected with adenovirus-5 wild-type and recombinant viruses at a moi of 100. Histochemical analysis was done as described i 
